ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2
Launched by JOHNS HOPKINS UNIVERSITY · Jul 14, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The ACCESS 2 study is looking at how a special camera that uses artificial intelligence can help more young people with diabetes get screened for eye problems, specifically diabetic retinopathy. Diabetic retinopathy is a serious eye condition that can happen when someone has diabetes for a long time. This study is important because it aims to reach underserved youth who might not get the eye exams they need.
To be part of this study, participants should be between the ages of 29 and 76 and must have been diagnosed with either Type 1 diabetes for at least three years or Type 2 diabetes. It's important that they haven’t had a diabetic eye exam in the last year. If eligible, participants will have a simple eye exam using the camera, which will help doctors check for any eye damage related to diabetes. This trial is currently recruiting participants and aims to make sure more young people get the vital eye care they need.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Meets American Diabetes Association (ADA) criteria for diabetic retinopathy screening:
- • Diagnosis of Type 1 diabetes for ≥3 years, and age 11 or in puberty
- • Diagnosis of Type 2 diabetes
- Exclusion Criteria:
- • Known diabetic eye exam in the last 12 months
About Johns Hopkins University
Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
Risa M Wolf, MD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials